Articles by Laura Litwin
Clinicians hypothesize that the genetic mutation, known as RUFY1-RET fusion, caused resistance to lorlatinib.
A multicenter study that included 21,062 patients who were seen from 2009-2021 in South Korea provided key insights.
Dr. Merritt shares new thoracic surgery research insights for patient selection in sublobar resection for early-stage NSCLC.
Clinical Considerations Surrounding Sublobar Resection in NSCLC: Dr. Merritt Discusses Recent Review
Robert E. Merritt, MD, MBA, FACS, shares insights on his systematic review of sublobar resection and lobectomy. 
The ORR of the external control group was 3%, while it was 36.8% in those who received amivantamab for NSCLC.
Learn how sublobar resection showed "comparable oncologic outcomes and complication rates" as lobectomy per a recent review.
For patients with NSCLC and EGFR mutations, amivantamab plus carboplatin-pemetrexed shows OS benefits versus chemo alone.
A new study illustrated the importance of exercise for patients with lung cancer who experience cancer-related fatigue.
Home-based exercise programs after lung cancer resection do not improve physical function in patients with NSCLC.
Study Highlights Importance of Pretreatment Frailty Assessments for Older Adults With Advanced NSCLC
Implementing pretreatment frailty assessments into clinical workflows may help identify patients at risk of poor outcomes.
Researchers evaluated if commercially available AI software was capable of detecting lung cancer in chest radiographs.
Researchers say the conventional criteria may underestimate the condition in Asian patients with lung cancer.
The new study is working to identify additional therapeutic combinations targeted towards patients with NSCLC and low PD-L1.
Veterans with high socioeconomic deprivation experience suboptimal access to pre- and postoperative care for NSCLC.
The burden of disease is expected to increase to 4.62 million new cases and 3.55 million deaths by 2050.
Patients with NSCLC, treated with an immunotherapy regimen, have a higher risk of pneumonitis with decreased lung volume.
An analysis of the CCTG BR.34 trial showed that bone metastasis correlated with worse outcomes in patients with NSCLC.
A novel dietary pattern was linked to lower lung cancer incidence in people who were former smokers
The study explored the relationship between sociodemographic disparities and access to minimally-invasive surgery for NSCLC.
For patients with Schlafen 11-positive ES-SCLC, atezolizumab plus talazoparib showed an PFS improvement after chemotherapy.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.